No Data
No Data
Taienkang (301263.SZ): 2023 equity distribution, 10 distributions of 3 yuan, share registration date May 22
Gelonghui, May 15 | Taienkang (301263.SZ) announced that the company's 2023 equity distribution plan is to distribute RMB 3.000000 in cash (tax included) to all shareholders for every 10 shares based on the company's current total share capital excluding 423,512,382 shares after 1,985,118 shares have been repurchased. The share registration date for this equity distribution is May 22, 2024, and the ex-dividend date is May 23, 2024.
Guangdong Taienkang Pharmaceutical's (SZSE:301263) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Guangdong Taienkang Pharmaceutical Co., Ltd.'s (SZSE:301263) recent weak earnings report didn't cause a big stock movement. However, we believe that investors should be aware of some underlying facto
Taienkang (301263.SZ): Application for registration and marketing license for the domestic production of methimazole tablets was accepted
Zhitong Finance App News, Taienkang (301263.SZ) announced that Shandong Huabo Kaisheng Biotechnology Co., Ltd. (“Huabo Kaisheng”), a wholly-owned subsidiary of the company, recently received the “Notice of Acceptance” of the application for registration and marketing of drugs produced domestically by methimazole tablets issued by the State Drug Administration. According to the announcement, methimazole is an imidazole antithyroid drug. By inhibiting the activity of thyroid peroxidase (TPO), a key enzyme in the thyroid gland, it blocks the absorption of the coupling of iodide and tyrosine in the thyroid gland, and hinders the synthesis of thyroid T4 and triiodothyronine T3. A
Guangdong Taienkang Pharmaceutical Co., Ltd.'s (SZSE:301263) Stock Is Going Strong: Have Financials A Role To Play?
Guangdong Taienkang Pharmaceutical (SZSE:301263) has had a great run on the share market with its stock up by a significant 6.6% over the last week. We wonder if and what role the company's financia
Taienkang (301263.SZ) announced its 2023 annual results, with net profit of 160 million yuan, a decrease of 8.26%
Taienkang (301263.SZ) released its 2023 annual report. The company's revenue was 761 million yuan,...
Taienkang (301263.SZ): Application for marketing license for topical hair loss treatment “minoxidil liniment” accepted
Taienkang (301263.SZ) announced that Shandong Huabo Kaisheng Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, recently...
No Data